Arvinas, Pfizer Present 'Encouraging' Preliminary Data for Prospective Breast Cancer Treatment

MT Newswires Live12-10

Arvinas (ARVN) and Pfizer (PFE) on Tuesday reported "encouraging" preliminary data from an ongoing phase 1b trial of their vepdegestrant drug candidate in combination with Eli Lilly's (LLY) abemaciclib kinase inhibitor in patients with a form of breast cancer.

Trial results from 16 patients with locally advanced or metastatic estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer demonstrated a tolerable safety profile for the combination of 200 milligrams of vepdegestrant daily with 150 milligrams of abemaciclib twice daily.

The drug combination showed a clinical benefit rate of 62.5% and an overall response rate of 26.7% among breast cancer patients previously treated with a CDK4/6 inhibitor, the companies said.

Arvinas shares were down more than 2% in recent trading, while Pfizer was off by about 1%.

Price: 25.00, Change: -0.08, Percent Change: -0.34

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490145830?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 23:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490145830","market":"us","top_or_hot":-1,"title":"Arvinas, Pfizer Present 'Encouraging' Preliminary Data for Prospective Breast Cancer Treatment","media":"MT Newswires Live","content":"<html><body><p> Arvinas (ARVN) and Pfizer (PFE) on Tuesday reported \"encouraging\" preliminary data from an ongoing phase 1b trial of their vepdegestrant drug candidate in combination with Eli Lilly's (LLY) abemaciclib kinase inhibitor in patients with a form of breast cancer.</p><p>Trial results from 16 patients with locally advanced or metastatic estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer demonstrated a tolerable safety profile for the combination of 200 milligrams of vepdegestrant daily with 150 milligrams of abemaciclib twice daily.</p><p>The drug combination showed a clinical benefit rate of 62.5% and an overall response rate of 26.7% among breast cancer patients previously treated with a CDK4/6 inhibitor, the companies said.</p><p>Arvinas shares were down more than 2% in recent trading, while Pfizer was off by about 1%.</p><p>Price: 25.00, Change: -0.08, Percent Change: -0.34</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arvinas, Pfizer Present 'Encouraging' Preliminary Data for Prospective Breast Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArvinas, Pfizer Present 'Encouraging' Preliminary Data for Prospective Breast Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-10 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Arvinas (ARVN) and Pfizer (PFE) on Tuesday reported \"encouraging\" preliminary data from an ongoing phase 1b trial of their vepdegestrant drug candidate in combination with Eli Lilly's (LLY) ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0058720904.USD","symbol_name":"联博国际健康护理基金A","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490145830","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490145830","pubTimestamp":1733843108,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Arvinas  and Pfizer  on Tuesday reported \"encouraging\" preliminary data from an ongoing phase 1b trial of their vepdegestrant drug candidate in combination with Eli Lilly's  abemaciclib kinase inhibitor in patients with a form of breast cancer.Trial results from 16 patients with locally advanced or metastatic estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer demonstrated a tolerable safety profile for the combination of 200 milligrams of vepdegestrant daily with 150 milligrams of abemaciclib twice daily.The drug combination showed a clinical benefit rate of 62.5% and an overall response rate of 26.7% among breast cancer patients previously treated with a CDK4/6 inhibitor, the companies said.Arvinas shares were down more than 2% in recent trading, while Pfizer was off by about 1%.Price: 25.00, Change: -0.08, Percent Change: -0.34","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0058720904.USD":"联博国际健康护理基金A","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4550":"红杉资本持仓","BK4588":"碎股","LLY":"礼来","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","SG9999015978.USD":"利安颠覆性创新基金A","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","SG9999014906.USD":"大华全球优质成长基金Acc USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","PFE.AU":"PANTERA MINERALS LTD","ARVN":"Arvinas Holding Company LLC","BK4516":"特朗普概念","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","BK4592":"伊斯兰概念","LU0238689110.USD":"贝莱德环球动力股票基金","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","BK4007":"制药","SGXZ81514606.USD":"大华环球创新基金A Acc USD","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","PFE":"辉瑞","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002224.SGD":"Allianz Global High Payout SGD"},"translate_title":"Arvinas和辉瑞提供了前瞻性乳腺癌治疗的“令人鼓舞”的初步数据","themeId":"f51f112c51cad6fb01d7527bc545b26e","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE.AU":1,"PFE":1,"ARVN":0.9,"LLY":0.9},"content_text":"Arvinas (ARVN) and Pfizer (PFE) on Tuesday reported \"encouraging\" preliminary data from an ongoing phase 1b trial of their vepdegestrant drug candidate in combination with Eli Lilly's (LLY) abemaciclib kinase inhibitor in patients with a form of breast cancer.Trial results from 16 patients with locally advanced or metastatic estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer demonstrated a tolerable safety profile for the combination of 200 milligrams of vepdegestrant daily with 150 milligrams of abemaciclib twice daily.The drug combination showed a clinical benefit rate of 62.5% and an overall response rate of 26.7% among breast cancer patients previously treated with a CDK4/6 inhibitor, the companies said.Arvinas shares were down more than 2% in recent trading, while Pfizer was off by about 1%.Price: 25.00, Change: -0.08, Percent Change: -0.34","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490145830"}